Crossject
Research Crossject (ALCJ) on Bullrun: market cap EUR 99.74M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALCJ
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyEUR
- Market capEUR 99.74M
- Financial periodFY2025
- Net income-EUR 10.37M
- Free cash flow-EUR 10.85M
Valuation Snapshot
latest market cap is EUR 99.74M.
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis.
Frequently asked questions
What is Crossject's market cap?
Crossject's market capitalization is EUR 99.74M.
What does Crossject do?
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose;